title: Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.
abstract: 175 patients with severe psoriasis of different types were treated with 10, 25, or 50 mg acitretin and compared with patients receiving 50 mg etretinate over a period of 8 weeks in a randomized, double-blind multicenter study in the Federal Republic of Germany. Plasma concentrations of etretinate and its metabolite acitretin were measured during therapy and also 3 weeks after cessation of treatment. After 4 weeks of treatment, a trend toward clinical improvement was shown in all groups with increasing dosage. Those groups receiving the lower acitretin doses (i.e., 10 and 25 mg/day) had more dropouts than the groups taking 50 mg acitretin or 50 mg etretinate. Complete remissions before the end of therapy occurred only among those receiving higher doses. Enlargement of psoriatic lesions, however, could be observed during treatment with both retinoids, despite improvement of other parameters, as measured by psoriasis area and severity index (PASI) and psoriasis severity index (PSI). After 8 weeks, a significant improvement was calculated by the PASI score and by a newly defined, corrected PASI score for all four dose regimens compared with baseline levels. A greater than 50% PSI score improvement was seen in 50% of patients treated with 10 mg acitretin, 40.5% with 25 mg acitretin, 53.8% with 50 mg acitretin, and 61.1% with 50 mg etretinate. No statistical differences were found among these groups at any time during the 8-week period. No new or unexpected side effects occurred during acitretin treatment. Moreover, cholesterol levels did not significantly change. Three weeks after cessation of drug administration, the plasma concentrations of acitretin were below the sensitivity level of the assay, whereas etretinate was still quantifiable. It is interesting that acitretin plasma concentrations during therapy with 50 mg acitretin were markedly lower (means = 18 ng/ml) than were acitretin levels during treatment with 50 mg etretinate (means = 36 ng/ml).
authors.affiliation: Department of Dermatology, University Medical Center Steglitz, Free University of Berlin, Federal Republic of Germany.
authors.forename: H
authors.initials: H
authors.lastname: Gollnick
authors.forename: R
authors.initials: R
authors.lastname: Bauer
authors.forename: C
authors.initials: C
authors.lastname: Brindley
authors.forename: C E
authors.initials: CE
authors.lastname: Orfanos
authors.forename: G
authors.initials: G
authors.lastname: Plewig
authors.forename: H
authors.initials: H
authors.lastname: Wokalek
authors.forename: E
authors.initials: E
authors.lastname: Hoting
mesh_terms: D017255:Acitretin; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005050:Etretinate / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D011897:Random Allocation; D014212:Tretinoin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D014212:Tretinoin; D005050:Etretinate; D017255:Acitretin